EXEL · Exelixis, Inc.
AI read · Bad for EXEL
The AI's read
Exelixis said the FDA extended review of its NDA for zanzalintinib by 3 months to March 3, 2027. The agency called Exelixis' updated safety and efficacy data a "major amendment," which triggered the extension. This delays any possible approval and potential drug sales, so I read the announcement as negative for Exelixis.